You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameZaleplon
Accession NumberDB00962  (APRD00411)
TypeSmall Molecule
GroupsApproved, Illicit, Investigational
DescriptionZaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States.
Structure
Thumb
Synonyms
3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide
External Identifiers
  • DEA No. 2781
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SonataCapsule10 mg/1OralPfizer Laboratories Div Pfizer Inc1999-08-13Not applicableUs
SonataCapsule5 mg/1OralPhysicians Total Care, Inc.2007-09-05Not applicableUs
SonataCapsule5 mg/1OralPfizer Laboratories Div Pfizer Inc1999-08-13Not applicableUs
SonataCapsule10 mg/1OralPhysicians Total Care, Inc.2004-04-01Not applicableUs
StarnocCapsule10 mgOralServier Canada Inc2000-06-272007-09-27Canada
StarnocCapsule5 mgOralPfizer Canada IncNot applicableNot applicableCanada
StarnocCapsule10 mgOralPfizer Canada IncNot applicableNot applicableCanada
StarnocCapsule5 mgOralServier Canada Inc2000-06-272007-09-27Canada
ZaleplonCapsule10 mg/1OralRebel Distributors Corp.2008-05-01Not applicableUs
ZaleplonCapsule5 mg/1OralRebel Distributors Corp.2008-05-01Not applicableUs
ZaleplonCapsule5 mg/1Oralbryant ranch prepack2008-05-01Not applicableUs
ZaleplonCapsule10 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-05Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ZaleplonCapsule10 mg/1Oralbryant ranch prepack2009-05-05Not applicableUs
ZaleplonCapsule5 mg/1OralAidarex Pharmaceuticals LLC2009-05-05Not applicableUs
ZaleplonCapsule10 mg/1OralUnit Dose Services2008-06-06Not applicableUs
ZaleplonCapsule5 mg/1OralNorthstar Rx LLC2010-06-23Not applicableUs
ZaleplonCapsule5 mg/1OralTeva Pharmaceuticals USA Inc2008-06-06Not applicableUs
ZaleplonCapsule5 mg/1OralAscend Laboratories, LLC2010-12-15Not applicableUs
ZaleplonCapsule5 mg/1OralRebel Distributors Corp2009-05-05Not applicableUs
ZaleplonCapsule5 mg/1OralPhysicians Total Care, Inc.2008-06-19Not applicableUs
ZaleplonCapsule5 mg/1OralCitron Pharma LLC2008-06-06Not applicableUs
ZaleplonCapsule, gelatin coated5 mg/1OralUpsher Smith Laboratories, Inc.2008-06-06Not applicableUs
ZaleplonCapsule5 mg/1OralAurobindo Pharma Limited2008-06-06Not applicableUs
ZaleplonCapsule10 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2009-05-05Not applicableUs
ZaleplonCapsule10 mg/1OralTeva Pharmaceuticals USA Inc2008-06-06Not applicableUs
ZaleplonCapsule10 mg/1OralH.J. Harkins Company, Inc.2010-12-15Not applicableUs
ZaleplonCapsule10 mg/1OralNorthstar Rx LLC2010-06-23Not applicableUs
ZaleplonCapsule10 mg/1OralAscend Laboratories, LLC2010-12-15Not applicableUs
ZaleplonCapsule5 mg/1OralPd Rx Pharmaceuticals, Inc.2011-12-02Not applicableUs
ZaleplonCapsule10 mg/1OralSt Marys Medical Park Pharmacy2010-12-15Not applicableUs
ZaleplonCapsule10 mg/1OralCitron Pharma LLC2008-06-06Not applicableUs
ZaleplonCapsule, gelatin coated10 mg/1OralUpsher Smith Laboratories, Inc.2008-06-06Not applicableUs
ZaleplonCapsule5 mg/1OralRebel Distributors Corp2009-05-05Not applicableUs
ZaleplonCapsule10 mg/1OralAurobindo Pharma Limited2008-06-06Not applicableUs
ZaleplonCapsule5 mg/1OralUnichem Pharmaceuticals (USA), Inc.2009-05-05Not applicableUs
ZaleplonCapsule5 mg/1OralMylan Pharmaceuticals Inc.2008-06-062016-10-13Us
ZaleplonCapsule10 mg/1OralA S Medication Solutions Llc2008-06-06Not applicableUs
ZaleplonCapsule5 mg/1OralWest Ward Pharmaceuticals Corp.2008-06-06Not applicableUs
ZaleplonCapsule5 mg/1OralPd Rx Pharmaceuticals, Inc.2008-06-06Not applicableUs
ZaleplonCapsule10 mg/1OralDIRECT RX2015-01-01Not applicableUs
ZaleplonCapsule10 mg/1OralA S Medication Solutions2009-05-05Not applicableUs
ZaleplonCapsule10 mg/1OralAidarex Pharmaceuticals LLC2009-05-05Not applicableUs
ZaleplonCapsule10 mg/1OralRebel Distributors Corp2009-05-05Not applicableUs
ZaleplonCapsule5 mg/1OralDispensing Solutions, Inc.2008-06-06Not applicableUs
ZaleplonCapsule10 mg/1OralUnichem Pharmaceuticals (USA), Inc.2009-05-05Not applicableUs
ZaleplonCapsule10 mg/1OralMylan Pharmaceuticals Inc.2008-06-062016-10-13Us
ZaleplonCapsule10 mg/1OralPhysicians Total Care, Inc.2008-06-19Not applicableUs
ZaleplonCapsule10 mg/1OralWest Ward Pharmaceuticals Corp.2008-06-06Not applicableUs
ZaleplonCapsule10 mg/1OralA S Medication Solutions Llc2008-06-06Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SonataCapsule5 mgOralMeda Ab1999-03-12Not applicableEu
SonataCapsule10 mgOralMeda Ab1999-03-12Not applicableEu
SonataCapsule5 mgOralMeda Ab1999-03-12Not applicableEu
SonataCapsule10 mgOralMeda Ab1999-03-12Not applicableEu
SonataCapsule5 mgOralMeda Ab1999-03-12Not applicableEu
SonataCapsule10 mgOralMeda Ab1999-03-12Not applicableEu
International Brands
NameCompany
ZalaplonNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIS62U433RMH
CAS number151319-34-5
WeightAverage: 305.3339
Monoisotopic: 305.127660127
Chemical FormulaC17H15N5O
InChI KeyHUNXMJYCHXQEGX-UHFFFAOYSA-N
InChI
InChI=1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3
IUPAC Name
N-(3-{3-cyanopyrazolo[1,5-a]pyrimidin-7-yl}phenyl)-N-ethylacetamide
SMILES
CCN(C(C)=O)C1=CC=CC(=C1)C1=CC=NC2=C(C=NN12)C#N
Pharmacology
IndicationFor the treatment of short-term treatment of insomnia in adults.
Structured Indications
PharmacodynamicsZaleplon is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class and is indicated for the short-term treatment of insomnia. While Zaleplon is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABABZ) receptor complex. Subunit modulation of the GABABZ receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Zaleplon also binds selectively to the CNS GABAA-receptor chloride ionophore complex at benzodiazepine(BZ) omega-1 (BZ1, ο1) receptors.
Mechanism of actionZaleplon exerts its action through subunit modulation of the GABABZ receptor chloride channel macromolecular complex. Zaleplon also binds selectively to the brain omega-1 receptor located on the alpha subunit of the GABA-A/chloride ion channel receptor complex and potentiates t-butyl-bicyclophosphorothionate (TBPS) binding.
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1Proteinyes
potentiator
HumanP14867 details
Translocator proteinProteinyes
other
HumanP30536 details
Related Articles
AbsorptionAbsorption Zaleplon is rapidly and almost completely absorbed following oral administration.
Volume of distribution
  • 1.4 L/kg
Protein bindingApproximately 60% (in vitro plasma protein binding).
Metabolism

Zaleplon is primarily metabolized by aldehyde oxidase.

SubstrateEnzymesProduct
Zaleplon
desethylzaleplonDetails
Route of eliminationZaleplon is metabolized primarily by the liver and undergoes significant presystemic metabolism. After oral administration, zaleplon is extensively metabolized, with less than 1% of the dose excreted unchanged in urine. Renal excretion of unchanged zaleplon accounts for less than 1% of the administered dose.
Half lifeApproximately 1 hour
Clearance
  • 1 L/h/kg
ToxicitySide effects include abdominal pain, amnesia, dizziness, drowsiness, eye pain, headache, memory loss, menstrual pain, nausea, sleepiness, tingling, weakness
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Zaleplon is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Zaleplon is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Aceprometazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Zaleplon.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Zaleplon is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zaleplon.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Zaleplon can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Zaleplon is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Amperozide.Experimental
AprepitantThe serum concentration of Zaleplon can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Zaleplon is combined with Aripiprazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Asenapine.Approved
AtazanavirThe metabolism of Zaleplon can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Zaleplon can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Azaperone.Vet Approved
AzelastineZaleplon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Zaleplon is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Zaleplon is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Zaleplon is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Zaleplon is combined with Benzyl alcohol.Approved
BexaroteneThe serum concentration of Zaleplon can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Zaleplon can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Zaleplon can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Zaleplon can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Zaleplon is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved
BromazepamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Bromazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Zaleplon.Approved, Investigational
BuprenorphineZaleplon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Zaleplon.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zaleplon.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Zaleplon is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Zaleplon is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Zaleplon is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Zaleplon.Approved, Illicit, Vet Approved
CarbamazepineThe serum concentration of Zaleplon can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Zaleplon is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Zaleplon is combined with Carisoprodol.Approved
CeritinibThe serum concentration of Zaleplon can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Zaleplon is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Zaleplon.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Zaleplon.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Chlorzoxazone.Approved
CimetidineThe metabolism of Zaleplon can be decreased when combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Zaleplon.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Zaleplon is combined with Citalopram.Approved
ClarithromycinThe metabolism of Zaleplon can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Zaleplon can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Zaleplon is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Zaleplon is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zaleplon.Approved, Illicit
ClotrimazoleThe metabolism of Zaleplon can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Zaleplon.Approved
CobicistatThe metabolism of Zaleplon can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Zaleplon.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Zaleplon.Approved, Illicit
ConivaptanThe serum concentration of Zaleplon can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Zaleplon can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zaleplon.Approved
CyclosporineThe metabolism of Zaleplon can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Zaleplon can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Zaleplon.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Zaleplon can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Zaleplon can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Zaleplon can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Zaleplon can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Zaleplon is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Zaleplon can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Zaleplon.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Zaleplon.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Zaleplon.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Zaleplon is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Zaleplon can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Zaleplon can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Zaleplon is combined with Diphenoxylate.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Zaleplon is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Zaleplon is combined with Doxepin.Approved
DoxycyclineThe metabolism of Zaleplon can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Zaleplon is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved, Illicit
DronedaroneThe metabolism of Zaleplon can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Zaleplon is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Zaleplon.Approved
EcgonineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Zaleplon is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Zaleplon can be decreased when it is combined with Efavirenz.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Zaleplon.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Zaleplon is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Zaleplon can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Zaleplon can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Zaleplon is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Zaleplon can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zaleplon.Approved
EthanolZaleplon may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Zaleplon.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Zaleplon.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Zaleplon can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Zaleplon is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zaleplon.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Zaleplon is combined with Flibanserin.Approved
FluconazoleThe metabolism of Zaleplon can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fludiazepam.Approved, Illicit
FlumazenilFlumazenil may decrease the sedative activities of Zaleplon.Approved
FlunarizineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Zaleplon.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zaleplon.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zaleplon.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Zaleplon can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Zaleplon can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Zaleplon can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Zaleplon can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Zaleplon is combined with Fospropofol.Approved, Illicit
Fusidic AcidThe serum concentration of Zaleplon can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Zaleplon is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Zaleplon is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Zaleplon is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Zaleplon is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Zaleplon.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zaleplon.Approved
HalothaneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Zaleplon is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Zaleplon is combined with Hexobarbital.Approved
HydrocodoneZaleplon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Zaleplon.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved
IdelalisibThe serum concentration of Zaleplon can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Iloperidone.Approved
ImatinibThe metabolism of Zaleplon can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Zaleplon can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Zaleplon can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Zaleplon.Approved, Vet Approved
IsradipineThe metabolism of Zaleplon can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Zaleplon can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Zaleplon can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Zaleplon can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Zaleplon is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Zaleplon.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Zaleplon.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Zaleplon is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Zaleplon is combined with Lofentanil.Illicit
LopinavirThe metabolism of Zaleplon can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Zaleplon.Approved
LovastatinThe metabolism of Zaleplon can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Zaleplon.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Zaleplon is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Zaleplon can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Zaleplon can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of Zaleplon can be decreased when used in combination with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Zaleplon is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zaleplon.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zaleplon.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Zaleplon.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Zaleplon.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Zaleplon.Approved
MethotrimeprazineZaleplon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Zaleplon.Approved
MetyrosineZaleplon may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Zaleplon can be decreased when used in combination with Mianserin.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Zaleplon.Approved, Illicit
MifepristoneThe serum concentration of Zaleplon can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Zaleplon is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved, Investigational
MirtazapineZaleplon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Zaleplon can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Zaleplon can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Zaleplon.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved, Investigational
NafcillinThe serum concentration of Zaleplon can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Zaleplon.Approved
NefazodoneThe metabolism of Zaleplon can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Zaleplon can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Zaleplon can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Zaleplon can be decreased when it is combined with Nevirapine.Approved
NilotinibThe metabolism of Zaleplon can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Zaleplon.Approved, Investigational
OlaparibThe metabolism of Zaleplon can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Zaleplon.Approved
OpiumThe risk or severity of adverse effects can be increased when Zaleplon is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Zaleplon can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineZaleplon may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Zaleplon is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Zaleplon can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zaleplon.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Zaleplon is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Zaleplon.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zaleplon.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Oxymorphone.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Zaleplon can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Paliperidone.Approved
ParaldehydeZaleplon may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zaleplon.Approved, Vet Approved
PentobarbitalThe serum concentration of Zaleplon can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved
PerazineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Zaleplon is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zaleplon.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Zaleplon.Approved
PhenobarbitalThe serum concentration of Zaleplon can be decreased when it is combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Zaleplon is combined with Phenoxyethanol.Approved
PhenytoinThe serum concentration of Zaleplon can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Zaleplon can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleZaleplon may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Zaleplon.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Zaleplon.Approved
PrimidoneThe serum concentration of Zaleplon can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Zaleplon.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zaleplon.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Zaleplon.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Zaleplon.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Zaleplon.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Zaleplon is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Quetiapine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Zaleplon can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zaleplon.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Zaleplon.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Zaleplon.Approved
RifabutinThe serum concentration of Zaleplon can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Zaleplon can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Zaleplon can be decreased when it is combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Zaleplon.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ritanserin.Investigational
RitonavirThe metabolism of Zaleplon can be decreased when combined with Ritonavir.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Romifidine.Vet Approved
RopiniroleZaleplon may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Zaleplon.Approved
RotigotineZaleplon may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Zaleplon.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Zaleplon is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Zaleplon is combined with Sage 547.Investigational
SaquinavirThe metabolism of Zaleplon can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zaleplon.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Zaleplon is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Zaleplon can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Zaleplon can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Zaleplon can be increased when it is combined with Simeprevir.Approved
Sodium oxybateZaleplon may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
St. John's WortThe serum concentration of Zaleplon can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Zaleplon can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zaleplon.Approved, Investigational
SulfisoxazoleThe metabolism of Zaleplon can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Zaleplon.Approved
SuvorexantZaleplon may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Zaleplon can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Zaleplon can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Zaleplon.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tetrodotoxin.Investigational
ThalidomideZaleplon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Zaleplon is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Zaleplon.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Zaleplon.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tiapride.Investigational
TiclopidineThe metabolism of Zaleplon can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tiletamine.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Zaleplon can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Zaleplon is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Zaleplon.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Zaleplon.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Zaleplon.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Zaleplon.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zaleplon.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Zaleplon.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Zaleplon is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Zaleplon.Approved, Investigational
VenlafaxineThe metabolism of Zaleplon can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Zaleplon can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Zaleplon is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Zaleplon can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Xylazine.Vet Approved
ZiconotideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Zaleplon can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zaleplon is combined with Zolazepam.Vet Approved
ZolpidemZaleplon may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zaleplon is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zaleplon is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zaleplon is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zaleplon is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Farhan Aslam, “Polymorphs of zaleplon and methods for the preparation thereof.” U.S. Patent US20020072527, issued June 13, 2002.

US20020072527
General References
  1. Dundar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T: Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol. 2004 Jul;19(5):305-22. [PubMed:15252823 ]
  2. Noguchi H, Kitazumi K, Mori M, Shiba T: Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats. J Pharmacol Sci. 2004 Mar;94(3):246-51. [PubMed:15037809 ]
  3. Ramakrishnan K, Scheid DC: Treatment options for insomnia. Am Fam Physician. 2007 Aug 15;76(4):517-26. [PubMed:17853625 ]
  4. Barbera J, Shapiro C: Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Saf. 2005;28(4):301-18. [PubMed:15783240 ]
  5. Dooley M, Plosker GL: Zaleplon: a review of its use in the treatment of insomnia. Drugs. 2000 Aug;60(2):413-45. [PubMed:10983740 ]
  6. Holm KJ, Goa KL: Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000 Apr;59(4):865-89. [PubMed:10804040 ]
  7. Patat A, Paty I, Hindmarch I: Pharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent. Hum Psychopharmacol. 2001 Jul;16(5):369-392. [PubMed:12404558 ]
External Links
ATC CodesN05CF03
AHFS Codes
  • 28:24.92
PDB EntriesNot Available
FDA labelDownload (66.1 KB)
MSDSDownload (57.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9751
Caco-2 permeable+0.5973
P-glycoprotein substrateNon-substrate0.6094
P-glycoprotein inhibitor INon-inhibitor0.5232
P-glycoprotein inhibitor IIInhibitor0.8239
Renal organic cation transporterNon-inhibitor0.745
CYP450 2C9 substrateNon-substrate0.8607
CYP450 2D6 substrateNon-substrate0.8551
CYP450 3A4 substrateSubstrate0.6341
CYP450 1A2 substrateNon-inhibitor0.5
CYP450 2C9 inhibitorInhibitor0.5986
CYP450 2D6 inhibitorNon-inhibitor0.9507
CYP450 2C19 inhibitorNon-inhibitor0.5238
CYP450 3A4 inhibitorNon-inhibitor0.8396
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7673
Ames testNon AMES toxic0.5372
CarcinogenicityNon-carcinogens0.6481
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6277 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9806
hERG inhibition (predictor II)Non-inhibitor0.8931
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • King pharmaceuticals research and development inc sub king pharmaceuticals inc
  • Aurobindo pharma ltd
  • Cipla ltd
  • Mylan pharmaceuticals inc
  • Orchid healthcare div orchid chemicals and pharmaceuticals ltd
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Unichem laboratories ltd
  • Upsher smith laboratories inc
  • West ward pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
CapsuleOral10 mg
CapsuleOral5 mg
CapsuleOral10 mg/1
CapsuleOral5 mg/1
Capsule, gelatin coatedOral10 mg/1
Capsule, gelatin coatedOral5 mg/1
Prices
Unit descriptionCostUnit
Sonata 10 mg capsule6.83USD capsule
Sonata 5 mg capsule5.26USD capsule
Zaleplon 5 mg capsule2.13USD capsule
Zaleplon 10 mg capsule2.09USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point157-159 °CNot Available
logP0.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0403 mg/mLALOGPS
logP2ALOGPS
logP1.53ChemAxon
logS-3.9ALOGPS
pKa (Strongest Basic)0.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area74.29 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity97.24 m3·mol-1ChemAxon
Polarizability32.09 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-01ot-3391000000-78a75199aa0ab8c426beView in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpyrimidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrimidine ring through a CC or CN bond. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentPhenylpyrimidines
Alternative Parents
Substituents
  • 4-phenylpyrimidine
  • Acetanilide
  • Pyrazolopyrimidine
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Acetamide
  • Tertiary carboxylic acid amide
  • Pyrazole
  • Azole
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Nitrile
  • Carbonitrile
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Patat A, Paty I, Hindmarch I: Pharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent. Hum Psychopharmacol. 2001 Jul;16(5):369-392. [PubMed:12404558 ]
  4. Barbera J, Shapiro C: Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Saf. 2005;28(4):301-18. [PubMed:15783240 ]
  5. Sanger DJ, Griebel G, Perrault G, Claustre Y, Schoemaker H: Discriminative stimulus effects of drugs acting at GABA(A) receptors: differential profiles and receptor selectivity. Pharmacol Biochem Behav. 1999 Oct;64(2):269-73. [PubMed:10515302 ]
  6. Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L: New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf. 2003;26(4):261-82. [PubMed:12608888 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
other
General Function:
Cholesterol binding
Specific Function:
Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in lipid metabolism (PubMed:24814875), but its precise physiological role is controversial. It is apparently not required for steroid hormone biosynthesis. Was initially identified as peripheral-type benz...
Gene Name:
TSPO
Uniprot ID:
P30536
Molecular Weight:
18827.81 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Foye, William O.;Williams, David A.;Lemke, Thomas L. (2002). Foye's Principles of Medicinal Chemistry (5th ed.). Lippincott Williams & Wilkins. [ISBN:0683307371 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xanthine dehydrogenase activity
Specific Function:
Oxidase with broad substrate specificity, oxidizing aromatic azaheterocycles, such as N1-methylnicotinamide and N-methylphthalazinium, as well as aldehydes, such as benzaldehyde, retinal, pyridoxal, and vanillin. Plays a key role in the metabolism of xenobiotics and drugs containing aromatic azaheterocyclic substituents. Participates in the bioactivation of prodrugs such as famciclovir, catalyz...
Gene Name:
AOX1
Uniprot ID:
Q06278
Molecular Weight:
147916.735 Da
References
  1. Lake BG, Ball SE, Kao J, Renwick AB, Price RJ, Scatina JA: Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica. 2002 Oct;32(10):835-47. [PubMed:12419014 ]
  2. Obach RS: Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos. 2004 Jan;32(1):89-97. [PubMed:14709625 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23